1Steinmann P,Keiser J, Bos R, et al. Schistosomiasis andwater resources development* systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis,2006,6:411-425.
8World Health Organization. The Control of Schistosomiasis, Second Report of the WHO Expert Committee[R]. WHO Techn Rep Ser, 1993, 830.
9Fallon PG, Doenhoff MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific[J]. Am J Trop Med Hyg, 1994, 51(1):83-88.
10Fallon PG, Sturrock RF, Capron A, et al. Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni[J] . Am J Trop Med Hyg, 1995,53(1): 61-62.
2Tchuem Tchuent6 LA, Momo SC, Stothard JR, et al. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenitalschistosomiasis in Cameroon [ J ]. Acta Tropica,2013,128(2) :275 -283.
3Webster BL, Diaw OT, Seye MM, et al. Praiquantel treatment of school children from single and mixed infection loci of intestinal and urogenitalschistosomiasis along the Senegal River Basin : moni- toring treatment success and re-infectlon patterns E J ]. Aeta Trop, 2013,128 (2) :292 - 302.
4de Souza AL, Andreani T, de Oliveira RN, et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment [ J ]. Int J Pharm, 2014, 463(1) :31 -37.
